Back to Search Start Over

Idelalisib immune-related toxicity is associated with improved treatment response.

Authors :
Wagner-Johnston, Nina D.
Sharman, Jeff
Furman, Richard R.
Salles, Gilles
Brown, Jennifer R.
Robak, Tadeusz
Gu, Lin
Xing, Guan
Chan, Rebecca J.
Rajakumaraswamy, Nishanthan
Gopal, Ajay K.
Source :
Leukemia & Lymphoma. Dec 2021, Vol. 62 Issue 12, p2915-2920. 6p.
Publication Year :
2021

Abstract

Idelalisib is associated with increased occurrence of immune-related adverse events (irAEs). Clinical observations suggest a correlation between immune checkpoint inhibitor–induced irAEs and survival outcomes in patients with solid tumors; however, this relationship in hematologic malignancies is not well understood. In a post hoc analysis of 3 registrational trials, we explored the relationship between Grade ≥3 diarrhea/colitis and alanine/aspartate transaminase (ALT/AST) elevation incidences and efficacy endpoints in patients with indolent non-Hodgkin lymphoma (iNHL), follicular lymphoma (FL), and chronic lymphocytic leukemia treated with idelalisib. Grade ≥3 diarrhea/colitis was associated with higher overall response rate (ORR) and longer progression-free survival (PFS) for all subgroups. Grade ≥3 ALT/AST elevations were associated with improved duration of response and overall survival for all subgroups and improved ORR and PFS for patients with FL or iNHL. Our analysis in hematologic malignancies showed a trend correlating idelalisib-induced Grade ≥3 irAEs with improved efficacy. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
10428194
Volume :
62
Issue :
12
Database :
Academic Search Index
Journal :
Leukemia & Lymphoma
Publication Type :
Academic Journal
Accession number :
153494510
Full Text :
https://doi.org/10.1080/10428194.2021.1948038